Advertisement

Evidence for the Current Management of Soft-tissue Sarcoma and Gastrointestinal Stromal Tumors and Emerging Directions

  • Fahima Dossa
    Affiliations
    Department of Surgery, University of Toronto, Stewart Building, 149 College Street, Toronto, Ontario M5T 1P5, Canada
    Search for articles by this author
  • Rebecca A. Gladdy
    Correspondence
    Corresponding author. Sinai Health System, 600 University Avenue, Suite 1225, Toronto, Ontario M5G 1X5, Canada.
    Affiliations
    Department of Surgery, University of Toronto, Stewart Building, 149 College Street, Toronto, Ontario M5T 1P5, Canada

    Division of Surgical Oncology, Department of Surgery, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

    Sinai Health System, 600 University Avenue, Suite 1225, Toronto, Ontario M5G 1X5, Canada
    Search for articles by this author
Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.07.010

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • World Health Organization Publication
        WHO classification of tumours: soft-tissue and bone tumours. International Agency for Research on Cancer, Geneva, Switzerland2020
        • Catton C.N.
        • O'Sullivan B.
        • Kotwall C.
        • et al.
        Outcome and prognosis in retroperitoneal soft-tissue sarcoma.
        Int J Radiat Oncol Biol Phys. 1994; 29: 1005-1010
        • Cancer Care Ontario
        Adult sarcoma management in ontario.
        Expert Panel Rep 2009. 2009;
        • Ray-Coquard I.
        • Thiesse P.
        • Ranchère-Vince D.
        • et al.
        Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft-tissue sarcomas.
        Ann Oncol. 2004; 15: 307-315
        • Gronchi A.
        • Miah A.
        • Dei Tos A.
        • et al.
        Soft-tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2021; 32: 1348-1365
        • Swallow C.J.
        • Strauss D.C.
        • Bonvalot S.
        • et al.
        Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the transatlantic australasian RPS working group.
        Ann Surg Oncol. 2021; 28: 7873-7888
        • Rosenberg S.A.
        • Tepper J.
        • Glatstein E.
        • et al.
        The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.
        Ann Surg. 1982; 196: 305
        • Ghert M.A.
        • Abudu A.
        • Driver N.
        • et al.
        The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft-tissue sarcoma of the extremity.
        Ann Surg Oncol. 2005; 12: 10-17
        • Smith H.G.
        • Thomas J.M.
        • Smith M.J.
        • et al.
        Major amputations for extremity soft-tissue sarcoma.
        Ann Surg Oncol. 2018; 25: 387-393
        • Karakousis C.
        • Proimakis C.
        • Walsh D.
        Primary soft-tissue sarcoma of the extremities in adults.
        J Br Surg. 1995; 82: 1208-1212
        • Raut C.P.
        • Swallow C.J.
        Are radical compartmental resections for retroperitoneal sarcomas justified?.
        Ann Surg Oncol. 2010; 17: 1481-1484
        • Cantin J.
        • McNeer G.P.
        • Chu F.C.
        • et al.
        The problem of local recurrence after treatment of soft-tissue sarcoma.
        Ann Surg. 1968; 168: 47
        • Pisters P.W.
        • Harrison L.B.
        • Leung D.H.
        • et al.
        Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft-tissue sarcoma.
        J Clin Oncol. 1996; 14: 859-868
        • Beane J.D.
        • Yang J.C.
        • White D.
        • et al.
        Efficacy of adjuvant radiation therapy in the treatment of soft-tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.
        Ann Surg Oncol. 2014; 21: 2484-2489
        • O'Sullivan B.
        • Davis A.M.
        • Turcotte R.
        • et al.
        Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.
        The Lancet. 2002; 359: 2235-2241
        • Davis A.M.
        • O'Sullivan B.
        • Turcotte R.
        • et al.
        Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft-tissue sarcoma.
        Radiother Oncol. 2005; 75: 48-53
        • Wang D.
        • Zhang Q.
        • Eisenberg B.L.
        • et al.
        Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 trial.
        J Clin Oncol. 2015; 33: 2231
        • O'Sullivan B.
        • Griffin A.M.
        • Dickie C.I.
        • et al.
        Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft-tissue sarcoma.
        Cancer. 2013; 119: 1878-1884
        • Lansu J.
        • Bovée J.V.
        • Braam P.
        • et al.
        Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial.
        JAMA Oncol. 2021; 7: e205865
        • Karakousis C.P.
        • Gerstenbluth R.
        • Kontzoglou K.
        • et al.
        Retroperitoneal sarcomas and their management.
        Arch Surg. 1995; 130: 1104-1109
        • Jaques D.P.
        • Coit D.G.
        • Hajdu S.I.
        • et al.
        Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum.
        Ann Surg. 1990; 212: 51-59
        • Mäkelä J.
        • Kiviniemi H.
        • Laitinen S.
        Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma.
        Eur J Surg Oncol. 2000; 26: 552-555
        • Jones J.J.
        • Catton C.N.
        • O’Sullivan B.
        • et al.
        Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.
        Ann Surg Oncol. 2002; 9: 346-354
        • Pisters P.W.
        • Ballo M.T.
        • Fenstermacher M.J.
        • et al.
        Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.
        J Clin Oncol. 2003; 21: 3092-3097
        • Pawlik T.M.
        • Pisters P.W.
        • Mikula L.
        • et al.
        Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate-or high-grade retroperitoneal soft-tissue sarcoma.
        Ann Surg Oncol. 2006; 13: 508-517
        • Smith M.J.
        • Ridgway P.F.
        • Catton C.N.
        • et al.
        Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial.
        Radiother Oncol. 2014; 110: 165-171
        • Roeder F.
        • Ulrich A.
        • Habl G.
        • et al.
        Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft-tissue sarcoma: interim analysis.
        BMC cancer. 2014; 14: 1-12
        • DeLaney T.F.
        • Mullen J.T.
        • Chen Y.-L.
        • et al.
        Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).
        Wolters Kluwer Health, Philadelphia, PA2021
        • Bonvalot S.
        • Gronchi A.
        • Le Péchoux C.
        • et al.
        Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1366-1377
      1. Callegaro D, RC AT, Strauss D, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: trial (STRASS) versus off-trial (STREXIT) results. Paper presented at: CTOS Annual Meeting2020.

        • Gronchi A.
        • Strauss D.C.
        • Miceli R.
        • et al.
        Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group.
        Ann Surg. 2016; 263: 1002-1009
        • Frustaci S.
        • Gherlinzoni F.
        • De Paoli A.
        • et al.
        Adjuvant chemotherapy for adult soft-tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
        J Clin Oncol. 2001; 19: 1238-1247
        • Frustaci S.
        • De Paoli A.
        • Eea B.
        • et al.
        Ifosfamide in the adjuvant therapy of soft-tissue sarcomas.
        Oncology. 2003; 65: 80-84
        • Collaboration SM-a
        Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.
        The Lancet. 1997; 350: 1647-1654
        • Pervaiz N.
        • Colterjohn N.
        • Farrokhyar F.
        • et al.
        A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
        Cancer. 2008; 113: 573-581
        • Woll P.J.
        • Reichardt P.
        • Le Cesne A.
        • et al.
        Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
        Lancet Oncol. 2012; 13: 1045-1054
        • Pasquali S.
        • Pizzamiglio S.
        • Touati N.
        • et al.
        The impact of chemotherapy on survival of patients with extremity and trunk wall soft-tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
        Eur J Cancer. 2019; 109: 51-60
        • Gronchi A.
        • Ferrari S.
        • Quagliuolo V.
        • et al.
        sarcoma Full-dose neoadjuvant anthracycline+ ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft-tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial.
        Ann Oncol. 2016; 27: vi587
        • Gronchi A.
        • Frustaci S.
        • Mercuri M.
        • et al.
        Short, full-dose adjuvant chemotherapy in high-risk adult soft-tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
        J Clin Oncol. 2012; 30: 850-856
        • Gortzak E.
        • Azzarelli A.
        • Buesa J.
        • et al.
        A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’adult soft-tissue sarcoma.
        Eur J Cancer. 2001; 37: 1096-1103
        • Gronchi A.
        • Ferrari S.
        • Quagliuolo V.
        • et al.
        Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
        Lancet Oncol. 2017; 18: 812-822
        • Tawbi H.A.
        • Burgess M.
        • Bolejack V.
        • et al.
        Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 1493-1501
        • Burgess M.A.
        • Bolejack V.
        • Schuetze S.
        • et al.
        Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
        J Clin Oncol. 2019; 37: 11015
        • Wilky B.A.
        • Trucco M.M.
        • Subhawong T.K.
        • et al.
        Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
        Lancet Oncol. 2019; 20: 837-848
        • Pollack S.M.
        • Redman M.W.
        • Baker K.K.
        • et al.
        Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial.
        JAMA Oncol. 2020; 6: 1778-1782
        • Roland C.L.
        • Keung E.Z.-Y.
        • Lazar A.J.
        • et al.
        Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
        Am J Clin Oncol. 2020; 38: 11505
        • Mowery Y.M.
        • Ballman K.V.
        • Riedel R.F.
        • et al.
        SU2C-SARC032: a phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft-tissue sarcoma.
        J Clin Oncol. 2018; 36: TPS11588
        • Keung E.Z.
        • Burgess M.
        • Salazar R.
        • et al.
        Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumabsarcoma-associated immune infiltrate and Anti-PD1 therapy.
        Clin Cancer Res. 2020; 26: 1258-1266
        • Somaiah N.
        • Conley A.P.
        • Lin H.Y.
        • et al.
        A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.
        Am J Clin Oncol. 2020; 38: 11509
        • Petitprez F.
        • de Reyniès A.
        • Keung E.Z.
        • et al.
        B cells are associated with survival and immunotherapy response in sarcoma.
        Nature. 2020; 577: 556-560
        • Demetri G.D.
        • Von Mehren M.
        • Blanke C.D.
        • et al.
        Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
        N Engl J Med. 2002; 347: 472-480
        • Blanke C.D.
        • Demetri G.D.
        • Von Mehren M.
        • et al.
        Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
        J Clin Oncol. 2008; 26: 620-625
        • DeMatteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
        Ann Surg. 2013; 258: 422
        • DeMatteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2009; 373: 1097-1104
        • Corless C.L.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
        J Clin Oncol. 2014; 32: 1563
        • Casali P.
        • Cesne A.L.
        • Velasco A.P.
        • et al.
        Time to definitive failure to the first tyrosine kinase inhibitor in localized gi stromal tumors treated with imatinib as an adjuvant: a european organisation for research and treatment of cancer soft-tissue and bone sarcoma group intergroup randomized trial in collaboration with the australasian gastro-intestinal trials group, UNICANCER, french sarcoma group, italian sarcoma group, and spanish group for research on sarcomas.
        J Clin Oncol. 2015; 33: 4276-4283
        • Joensuu H.
        • Eriksson M.
        • Hall K.S.
        • et al.
        One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
        JAMA. 2012; 307: 1265-1272
        • Joensuu H.
        • Eriksson M.
        • Hall K.S.
        • et al.
        Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up.
        JAMA Oncol. 2020; 6: 1241-1246
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial.
        J Clin Oncol. 2016; 34: 244-250
        • Raut C.P.
        • Espat N.J.
        • Maki R.G.
        • et al.
        Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate-or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial.
        JAMA Oncol. 2018; 4: e184060
        • Andtbacka R.H.
        • Ng C.S.
        • Scaife C.L.
        • et al.
        Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
        Ann Surg Oncol. 2007; 14: 14-24
        • Sjölund K.
        • Andersson A.
        • Nilsson E.
        • et al.
        Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
        World J Surg. 2010; 34: 2090-2097
        • Eisenberg B.L.
        • Harris J.
        • Blanke C.D.
        • et al.
        Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
        J Surg Oncol. 2009; 99: 42-47
        • Wang D.
        • Zhang Q.
        • Blanke C.D.
        • et al.
        Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
        Ann Surg Oncol. 2012; 19: 1074-1080
        • Kurokawa Y.
        • Yang H.K.
        • Cho H.
        • et al.
        Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
        Br J Cancer. 2017; 117: 25-32
        • McAuliffe J.C.
        • Hunt K.K.
        • Lazar A.J.
        • et al.
        A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
        Ann Surg Oncol. 2009; 16: 910-919